
Telomir Pharmaceuticals, Inc.
TELO·NASDAQ
Last updated as of 2026-06-09 15:48 EST. Stock price information is sourced from TradingView and reflects real-time market prices.
Insights
Calculator
News
TELO stock price change
On the last trading day, TELO stock closed at 1.21 USD, with a price change of -4.72% for the day.
Trade spot stocks (24/7)Trending stocks
About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn moreTELO key data
Previous close1.21 USD
Market cap83.22M USD
Volume73.37K
P/E ratio-
Dividend yield (TTM)0.00%
Dividend amount-
Last ex-dividend date-
Last payment date-
EPS diluted (TTM)-0.29 USD
Net income (FY)−10.41M USD
Revenue (FY)0.00 USD
Next report dateSep 2, 2026
EPS estimate-
Revenue estimate-
Shares float18.49M
Beta (1Y)0.68

Telomir Pharmaceuticals, Inc. overview
Sector
Health technology
Industry
Pharmaceuticals: Major
CEO
Erez Aminov
Headquarters
Miami
Website
telomirpharma.com
Founded
2021
Employees (FY)
2
Change (1Y)
−3 −60.00%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
−5.21M USD
TELO stock price forecast
According to technical indicators for TELO stock, the price is likely to fluctuate within the range of 1.38–1.50 USD over the next week. Market analysts predict that the price of TELO stock will likely fluctuate within the range of 1.36–1.72 USD over the next months.
Based on 1-year price forecasts from 28 analysts, the highest estimate is 2.40 USD, while the lowest estimate is 0.89 USD.
For more information, please see the
TELO stock price forecast
page.
Latest TELO stock news
Telomir Pharmaceuticals Inc's latest research shows that the company has achieved extensive tumor cell death rates in human triple-negative breast cancer experimental models.
老虎证券2026-02-17 13:20:58
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer
Finviz2026-03-31 12:06:48
According to a filing submitted to the U.S. Securities and Exchange Commission, biopharmaceutical company Telomir Pharmaceuticals has officially appointed Andriy Mushak as its part-time Chief Financial Officer, with the appointment scheduled to take effect on June 6, 2026.
老虎证券2026-06-08 21:09:10
Telomir Pharmaceuticals Inc's latest research shows that the company has achieved extensive tumor cell death rates in human triple-negative breast cancer experimental models.
老虎证券2026-02-17 13:20:58
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer
Finviz2026-03-31 12:06:48
According to a filing submitted to the U.S. Securities and Exchange Commission, biopharmaceutical company Telomir Pharmaceuticals has officially appointed Andriy Mushak as its part-time Chief Financial Officer, with the appointment scheduled to take effect on June 6, 2026.
老虎证券2026-06-08 21:09:10


